Somapacitan in Children Born SGA: 52-Week Efficacy, Safety, and IGF-I Response Results From the Phase 2 REAL5 Study
A sustained dose-dependent growth response was demonstrated for somapacitan after 52 weeks of treatment. Overall, somapacitan 0.24 mg/kg/week provides similar efficacy, safety, and tolerability, as well as comparable bioactive and total IGF-I response, as daily GH (0.067 mg/kg/day) in children born SGA.
Authors
- Rasmus Juul Kildemoes (ORCID: https://orcid.org/0000-0002-0965-9333)
- Reiko Horikawa (ORCID: https://orcid.org/0000-0003-3429-3246)
- Anders Krogh Lemminger (ORCID: https://orcid.org/0000-0002-7929-7147)
- Masanobu Kawai (ORCID: https://orcid.org/0000-0003-4466-1559)
- Jan Frystyk (ORCID: https://orcid.org/0000-0002-5379-0961)
- Nehama Zuckerman‐Levin (ORCID: https://orcid.org/0000-0002-5372-8113)
- Anders Juul (ORCID: https://orcid.org/0000-0002-0534-4350)
- Agnès Linglart (ORCID: https://orcid.org/0000-0003-3455-002X)
- Philippe Backeljauw (ORCID: https://orcid.org/0000-0003-2398-9520)
- Michael Højby
Institutions
- University of Copenhagen (DK)
- Cincinnati Children's Hospital Medical Center (US)
- Inserm (FR)
- University of Southern Denmark (DK)
- Novo Nordisk (Denmark) (DK)
- Université Paris-Saclay (FR)
- Rambam Health Care Campus (IL)
- Odense University Hospital (DK)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
- Osaka Women's and Children's Hospital (JP)
- Assistance Publique – Hôpitaux de Paris (FR)
- Rappaport Family Institute for Research in the Medical Sciences (IL)
- National Center For Child Health and Development (JP)
- Bicêtre Hospital (FR)
- University of Cincinnati (US)
Publication Details
- Journal
- The Journal of Clinical Endocrinology & Metabolism
- Published
- 2024-09-13
- DOI
- https://doi.org/10.1210/clinem/dgae616
- Citations
- 7
- Primary Topic
- Growth Hormone and Insulin-like Growth Factors
- Type
- article
- Field-Weighted Citation Impact
- 2.50
Funders
- Novo Nordisk